Zurcher Kantonalbank Zurich Cantonalbank Raises Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 28.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 399,232 shares of the medical research company’s stock after purchasing an additional 89,190 shares during the quarter. Thermo Fisher Scientific comprises approximately 0.8% of Zurcher Kantonalbank Zurich Cantonalbank’s investment portfolio, making the stock its 17th largest position. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.10% of Thermo Fisher Scientific worth $211,908,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in TMO. Vanguard Group Inc. raised its position in shares of Thermo Fisher Scientific by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock worth $16,582,503,000 after acquiring an additional 180,618 shares in the last quarter. Morgan Stanley grew its stake in Thermo Fisher Scientific by 0.4% during the 3rd quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock worth $6,285,838,000 after buying an additional 50,736 shares during the last quarter. Moneta Group Investment Advisors LLC grew its stake in Thermo Fisher Scientific by 104,536.8% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock worth $4,601,150,000 after buying an additional 8,347,260 shares during the last quarter. Providence Capital Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 61,754.7% in the 1st quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock valued at $10,136,000 after purchasing an additional 5,832,730 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $3,105,677,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Royal Bank of Canada lifted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Raymond James boosted their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. HSBC initiated coverage on Thermo Fisher Scientific in a report on Monday, December 18th. They issued a “buy” rating and a $610.00 price target for the company. Finally, Evercore ISI upped their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $601.56.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now directly owns 49,155 shares in the company, valued at approximately $27,311,992.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares of the company’s stock, valued at $660,192.79. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Down 0.6 %

TMO stock traded down $3.22 during trading on Tuesday, reaching $554.65. 1,010,297 shares of the stock traded hands, compared to its average volume of 1,539,256. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The business’s 50 day moving average price is $571.79 and its 200-day moving average price is $526.53. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The firm has a market capitalization of $211.72 billion, a PE ratio of 35.97, a P/E/G ratio of 2.38 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same quarter last year, the firm earned $5.40 earnings per share. The company’s revenue for the quarter was down 4.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were issued a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.